Loss of CYLD promotes splenic marginal zone lymphoma
Abstract Splenic marginal zone lymphoma (SMZL) is a distinct clinical and pathological entity among marginal zone lymphomas. Genetic and microenvironmental factors leading to aberrant activation of the NF‐κB pathway have been implicated in SMZL pathogenesis. CYLD is a negative regulator of NF‐κB and...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wiley
2025-03-01
|
| Schriftenreihe: | HemaSphere |
| Online-Zugang: | https://doi.org/10.1002/hem3.70098 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
